3 drug policy questions to watch in 2026

What’s Happening

Okay so The Trump administration has shown strong interest in furthering psychedelics as therapy, and cannabis too.

Politics Politics STAT Plus: The 3 biggest issues to watch in vaccine policy in 2026 By Daniel Payne Pharma Pharma STAT Plus: Major pharma companies may avoid Medicare experiments’ forced price cuts By John Wilkerson and Elaine Chen D. Diagnosis STAT Plus: Trump moves to require lower drug prices in Medicare By John Wilkerson A STAT Examination A STAT Examination Trump administration’s plan to shrink vaccine schedule sends health sector scrambling By Daniel Payne , Chelsea Cirruzzo , and Helen Branswell Business Business STAT Plus: Pharmaceutical industry evades drug price transparency, again By Bob Herman STAT Plus: FDA voucher program has become vehicle for political interference in drug review decisions, staffers say By Lizzy Lawrence STAT Plus: I’m the former head of Pfizer R&D. (shocking, we know)

I’m worried about biopharma’s future By John L.

Why This Matters

LaMattina STAT Plus: The Worst Biopharma CEO of 2025 made decisions with tragic consequences By Adam Feuerstein STAT Plus: Data on Humana’s clinics looked dismal. Then its corporate research machine got to work By Casey Ross and Tara Bannow STAT Plus: RFK Jr.

This is the kind of health news that affects everyday decisions.

The Bottom Line

This story is still developing, and we’ll keep you updated as more info drops.

Sound off in the comments.